ABSTRACT
Background DDX3X syndrome is a recently identified genetic disorder that accounts for 1-3% of cases of unexplained developmental delay (DD) and/or intellectual disability (ID) in females and is associated with motor and language delays, and autism spectrum disorder (ASD). To date, the published phenotypic characterization of this syndrome has primarily relied on medical record review; in addition, the behavioral dimensions of the syndrome have not been fully explored.
Methods We carried out multi-day, prospective, detailed phenotyping of DDX3X syndrome in 14 females and 1 male, focusing on behavioral, psychological, and neurological measures; three participants in this cohort have been previously reported. We compared results against population norms and contrasted phenotypes between individuals harboring either (i) protein-truncating variants or (ii) missense variants and in-frame deletions.
Results Eighty percent of individuals met criteria for ID, 60% for ASD and 53% for attention-deficit/hyperactivity disorder (ADHD). Motor and language delays were common as were sensory processing abnormalities. The cohort included 5 missense, 3 intronic/splice-site, 2 nonsense, 2 frameshift, 2 in-frame deletions, and one initiation codon variant. Genotype-phenotype correlations indicated that missense variants/in-frame deletions were associated with more severe language, motor, and adaptive deficits in comparison to protein-truncating variants.
Limitations Sample size is modest, however, DDX3X is a rare and underdiagnosed disorder.
Conclusion This study, representing a first, prospective, detailed characterization of DDX3X syndrome, extends our understanding of the neurobehavioral phenotype. Gold-standard diagnostic approaches demonstrated high rates of ID, ASD, and ADHD. In addition, sensory deficits were observed to be a key part of the syndrome. Even with a modest sample, we observe evidence for genotype-phenotype correlations with missense variants/in-frame deletions yielding a more severe phenotype.
Competing Interest Statement
A. Kolevzon receives research support from AMO Pharma and consults to Ovid Therapeutics, Acadia, and Sema4. PMS and Mount Sinai licensed the Sensory Assessment for Neurodevelopmental Disorders (SAND) licensed by PMS to Stoelting, Co. No other competing interests to declare.
Funding Statement
Funding was provided by the Beatrice and Samuel A. Seaver Foundation. The study sponsors had no role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. SDR is a Fascitelli Research Scholar. MSB is a Seaver Faculty Scholar.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Parents or legal guardians of all participants in this study provided informed consent prior to study participation. This study was approved by the Mouth Sinai Institutional Review Board, Program for the Protection of Human Subjects (Study ID: 98- 436).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Lara.Tang{at}mssm.edu, Tess.Levy{at}mssm.edu, Sylvia.Guillory{at}mssm.edu, Danielle.Halpern{at}mssm.edu, Jessica.Zweifach{at}mssm.edu, Ivy.Giserman-Kiss{at}mssm.edu, Jennifer.Foss-Feig{at}mssm.edu, Yitzchak.Frank{at}mssm.edu, Reymundo.Lozano{at}mssm.edu, Puneet.Belani{at}mountsinai.org, Christina.Layton{at}mssm.edu, Emanuel.Frowner{at}mssm.edu, Michael.Breen{at}mssm.edu, Silvia.DeRubeis{at}mssm.edu, Ana.Kostic{at}mssm.edu, Alexander.Kolevzon{at}mssm.edu, Joseph.Buxbaum{at}mssm.edu, Paige.Siper{at}mssm.edu, Dorothy.Grice{at}mssm.edu
List of abbreviations
- ADHD
- Attention Deficit/Hyperactivity Disorder
- ADI
- Autism Diagnostic Interview
- ADI-R
- Autism Diagnostic Interview-Revised
- ADOS-2
- Autism Diagnostic Observation Schedule, Second Edition
- ASD
- Autism Spectrum Disorder
- BMI
- Body Mass Index
- CBCL
- Achenbach Child Behavior Checklist
- DAS-II
- Differential Ability Scales-Second Edition
- DCDQ
- Developmental Coordination Disorder Questionnaire
- DD
- Developmental Delay
- DQ
- Developmental Quotient
- DSM-5
- Diagnostic and Statistical Manual, Fifth Edition ID Intellectual Disability
- IQ
- Intellectual Quotient
- MCDI
- MacArthur-Bates Communicative Development Inventory
- MRI
- Magnetic Resonance Imaging
- Mullen
- Scales Mullen Scales of Early Learning
- NICU
- Neonatal Intensive Care Unit
- NDDs
- Neurodevelopmental Disorders
- PDDBI
- Pervasive Developmental Disorder Behavior Inventory
- PMG
- Polymicrogyria
- PTV
- Protein Truncating Variant
- RBS-R
- Repetitive Behavior Scale-Revised
- SAND
- Sensory Assessment for Neurodevelopmental Disorders
- SB-5
- Stanford-Binet Intelligence Scales, Fifth Edition
- SRS-2
- Social Responsiveness Scale, Second Edition
- SSP
- Short Sensory Profile
- TD
- Typically Developing
- Vineland-3
- Vineland Adaptive Behavior Scales, Third Edition
- VMI-6
- Beery-Buktenica Developmental Test of Visual-Motor Integration, Sixth Edition
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.